118 related articles for article (PubMed ID: 30040270)
1. [Recent treatment results for metastatic melanoma: data from the Dutch Melanoma Treatment Registry].
van Zeijl MCT; van den Eertwegh AJM; Wouters MWJM; Jochems A; Schouwenburg MG; Haanen JBAG; Aarts MJ; van den Berkmortel FWPJ; de Groot JWB; Hospers GAP; Kapiteijn E; Koornstra RH; Piersma D; van Rijn RS; Suijkerbuijk KPM; Ten Tije AJ; van der Veldt AAM; Vreugdenhil G; van der Hoeven KJM
Ned Tijdschr Geneeskd; 2018 Jun; 162():. PubMed ID: 30040270
[TBL] [Abstract][Full Text] [Related]
2. Dutch Melanoma Treatment Registry: Quality assurance in the care of patients with metastatic melanoma in the Netherlands.
Jochems A; Schouwenburg MG; Leeneman B; Franken MG; van den Eertwegh AJ; Haanen JB; Gelderblom H; Uyl-de Groot CA; Aarts MJ; van den Berkmortel FW; Blokx WA; Cardous-Ubbink MC; Groenewegen G; de Groot JW; Hospers GA; Kapiteijn E; Koornstra RH; Kruit WH; Louwman MW; Piersma D; van Rijn RS; Ten Tije AJ; Vreugdenhil G; Wouters MW; van der Hoeven JJ
Eur J Cancer; 2017 Feb; 72():156-165. PubMed ID: 28030784
[TBL] [Abstract][Full Text] [Related]
3. Survival after intratumoral interleukin-2 treatment of 72 melanoma patients and response upon the first chemotherapy during follow-up.
Weide B; Eigentler TK; Pflugfelder A; Leiter U; Meier F; Bauer J; Schmidt D; Radny P; Pföhler C; Garbe C
Cancer Immunol Immunother; 2011 Apr; 60(4):487-93. PubMed ID: 21174093
[TBL] [Abstract][Full Text] [Related]
4. Improvement of overall survival in stage IV melanoma patients during 2011-2014: analysis of real-world data in 441 patients of the German Central Malignant Melanoma Registry (CMMR).
Forschner A; Eichner F; Amaral T; Keim U; Garbe C; Eigentler TK
J Cancer Res Clin Oncol; 2017 Mar; 143(3):533-540. PubMed ID: 27878363
[TBL] [Abstract][Full Text] [Related]
5. Survival outcomes of patients with advanced melanoma from 2013 to 2017: Results of a nationwide population-based registry.
van Zeijl MCT; de Wreede LC; van den Eertwegh AJM; Wouters MWJM; Jochems A; Schouwenburg MG; Aarts MJB; van Akkooi ACJ; van den Berkmortel FWPJ; de Groot JWB; Hospers GAP; Kapiteijn E; Piersma D; van Rijn RS; Suijkerbuijk KPM; Ten Tije AJ; van der Veldt AAM; Vreugdenhil G; van der Hoeven JJM; Haanen JBAG
Eur J Cancer; 2021 Feb; 144():242-251. PubMed ID: 33373869
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcome of patients with metastatic melanoma of unknown primary in the era of novel therapy.
Verver D; Grünhagen DJ; van Akkooi ACJ; Aarts MJB; van den Berkmortel FWPJ; van den Eertwegh AJM; de Groot JWB; Boers-Sonderen MJ; Haanen JBAG; Hospers GAP; Kapiteijn E; Piersma D; van Rijn RS; Suijkerbuijk KPM; Tije AJT; Vreugdenhil G; Verhoef C; van der Veldt AAM
Cancer Immunol Immunother; 2021 Nov; 70(11):3123-3135. PubMed ID: 33774697
[TBL] [Abstract][Full Text] [Related]
7. Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastases.
Zaremba A; Philip M; Hassel JC; Glutsch V; Fiocco Z; Loquai C; Rafei-Shamsabadi D; Gutzmer R; Utikal J; Haferkamp S; Reinhardt L; Kähler KC; Weishaupt C; Moreira A; Thoms KM; Wilhelm T; Pföhler C; Roesch A; Ugurel S; Zimmer L; Stadtler N; Sucker A; Kiecker F; Heinzerling L; Meier F; Meiss F; Schlaak M; Schilling B; Horn S; Schadendorf D; Livingstone E
Eur J Cancer; 2021 Jul; 152():139-154. PubMed ID: 34102453
[TBL] [Abstract][Full Text] [Related]
8. Prognostic score for patients with advanced melanoma treated with ipilimumab.
Diem S; Kasenda B; Martin-Liberal J; Lee A; Chauhan D; Gore M; Larkin J
Eur J Cancer; 2015 Dec; 51(18):2785-91. PubMed ID: 26597444
[TBL] [Abstract][Full Text] [Related]
9. Ipilimumab and Stereotactic Radiosurgery Versus Stereotactic Radiosurgery Alone for Newly Diagnosed Melanoma Brain Metastases.
Patel KR; Shoukat S; Oliver DE; Chowdhary M; Rizzo M; Lawson DH; Khosa F; Liu Y; Khan MK
Am J Clin Oncol; 2017 Oct; 40(5):444-450. PubMed ID: 26017484
[TBL] [Abstract][Full Text] [Related]
10. Predictive factors for the development of brain metastasis in advanced unresectable metastatic melanoma.
Bedikian AY; Wei C; Detry M; Kim KB; Papadopoulos NE; Hwu WJ; Homsi J; Davies M; McIntyre S; Hwu P
Am J Clin Oncol; 2011 Dec; 34(6):603-10. PubMed ID: 21150567
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors in 1,521 melanoma patients with distant metastases.
Barth A; Wanek LA; Morton DL
J Am Coll Surg; 1995 Sep; 181(3):193-201. PubMed ID: 7670677
[TBL] [Abstract][Full Text] [Related]
12. Stage-IV melanoma and pulmonary metastases: factors predictive of survival.
Neuman HB; Patel A; Hanlon C; Wolchok JD; Houghton AN; Coit DG
Ann Surg Oncol; 2007 Oct; 14(10):2847-53. PubMed ID: 17680317
[TBL] [Abstract][Full Text] [Related]
13. The antibacterial substance, taurolidine in the second/third-line treatment of very advanced stage IV melanoma including brain metastases: results of a phase 2, open-label study.
Imhof L; Goldinger SM; Baumann K; Schad K; French LE; Röthlisberger P; Dummer R
Melanoma Res; 2011 Feb; 21(1):80-3. PubMed ID: 21052029
[TBL] [Abstract][Full Text] [Related]
14. Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy).
Di Giacomo AM; Danielli R; Calabrò L; Bertocci E; Nannicini C; Giannarelli D; Balestrazzi A; Vigni F; Riversi V; Miracco C; Biagioli M; Altomonte M; Maio M
Cancer Immunol Immunother; 2011 Apr; 60(4):467-77. PubMed ID: 21170646
[TBL] [Abstract][Full Text] [Related]
15. Nationwide Outcomes of Advanced Melanoma According to BRAFV600 Status.
van Breeschoten J; Wouters MWJM; de Wreede LC; Hilarius DH; Haanen JB; Blank CU; Aarts MJB; van den Berkmortel FWPJ; de Groot JB; Hospers GAP; Kapiteijn E; Piersma D; van Rijn RS; Suijkerbuijk KPM; Blokx WAM; Ten Tije AJ; van der Veldt AAM; Vreugdenhil G; Boers MJ; van den Eertwegh AJM
Am J Clin Oncol; 2021 Feb; 44(2):82-89. PubMed ID: 33332931
[TBL] [Abstract][Full Text] [Related]
16. Survival trends among patients with metastatic melanoma in the pretargeted and the post-targeted era: a US population-based study.
Uprety D; Bista A; Chennamadhavuni A; Niroula A; Jafri SIM; Smith A; Arjyal L
Melanoma Res; 2018 Feb; 28(1):56-60. PubMed ID: 29023264
[TBL] [Abstract][Full Text] [Related]
17. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial.
Di Giacomo AM; Ascierto PA; Pilla L; Santinami M; Ferrucci PF; Giannarelli D; Marasco A; Rivoltini L; Simeone E; Nicoletti SV; Fonsatti E; Annesi D; Queirolo P; Testori A; Ridolfi R; Parmiani G; Maio M
Lancet Oncol; 2012 Sep; 13(9):879-86. PubMed ID: 22894884
[TBL] [Abstract][Full Text] [Related]
18. Pathologic complete response to intralesional interleukin-2 therapy associated with improved survival in melanoma patients with in-transit disease.
Hassan S; Petrella TM; Zhang T; Kamel-Reid S; Nordio F; Baccarelli A; Sade S; Naert K; Habeeb AA; Ghazarian D; Wright FC
Ann Surg Oncol; 2015; 22(6):1950-8. PubMed ID: 25366584
[TBL] [Abstract][Full Text] [Related]
19. Treatment patterns, outcomes, and resource utilization of patients with metastatic melanoma in the U.K.: the MELODY study.
Lorigan P; Marples M; Harries M; Wagstaff J; Dalgleish AG; Osborne R; Maraveyas A; Nicholson S; Davidson N; Wang Q; Pericleous L; Bapat U; Middleton MR
Br J Dermatol; 2014 Jan; 170(1):87-95. PubMed ID: 23855404
[TBL] [Abstract][Full Text] [Related]
20. Association of Innovations in Radiotherapy and Systemic Treatments With Clinical Outcomes in Patients With Melanoma Brain Metastasis From 2007 to 2016.
Brastianos HC; Nguyen P; Sahgal A; Eisenhauer EA; Baetz T; Hanna TP
JAMA Netw Open; 2020 Jul; 3(7):e208204. PubMed ID: 32663310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
